595 related articles for article (PubMed ID: 31191560)
1. Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180.
Mai Y; Nishie W; Izumi K; Shimizu H
Front Immunol; 2019; 10():1224. PubMed ID: 31191560
[TBL] [Abstract][Full Text] [Related]
2. Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization.
García-Díez I; Ivars-Lleó M; López-Aventín D; Ishii N; Hashimoto T; Iranzo P; Pujol RM; España A; Herrero-Gonzalez JE
Int J Dermatol; 2018 Jul; 57(7):810-816. PubMed ID: 29682739
[TBL] [Abstract][Full Text] [Related]
3. Normal human skin is superior to monkey oesophagus substrate for detection of circulating BP180-NC16A-specific IgG antibodies in bullous pemphigoid.
Emtenani S; Yuan H; Lin C; Pan M; Hundt JE; Schmidt E; Komorowski L; Stanley JR; Hammers CM
Br J Dermatol; 2019 May; 180(5):1099-1106. PubMed ID: 30315657
[TBL] [Abstract][Full Text] [Related]
4. Dipeptidyl peptidase IV inhibitor-associated bullous pemphigoid: a recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics.
Nishie W
Immunol Med; 2019 Mar; 42(1):22-28. PubMed ID: 31169082
[TBL] [Abstract][Full Text] [Related]
5. IgG4 and IgE are the major immunoglobulins targeting the NC16A domain of BP180 in Bullous pemphigoid: serum levels of these immunoglobulins reflect disease activity.
Döpp R; Schmidt E; Chimanovitch I; Leverkus M; Bröcker EB; Zillikens D
J Am Acad Dermatol; 2000 Apr; 42(4):577-83. PubMed ID: 10727301
[TBL] [Abstract][Full Text] [Related]
6. Clinical and Immunological Profiles of 14 Patients With Bullous Pemphigoid Without IgG Autoantibodies to the BP180 NC16A Domain.
Nakama K; Koga H; Ishii N; Ohata C; Hashimoto T; Nakama T
JAMA Dermatol; 2018 Mar; 154(3):347-350. PubMed ID: 29299596
[TBL] [Abstract][Full Text] [Related]
7. Bullous pemphigoid of childhood: autoantibodies target the same epitopes within the NC16A domain of BP180 as autoantibodies in bullous pemphigoid of adulthood.
Chimanovitch I; Hamm H; Georgi M; Kroiss M; Stolz W; Apitz C; Bröcker EB; Zillikens D
Arch Dermatol; 2000 Apr; 136(4):527-32. PubMed ID: 10768652
[TBL] [Abstract][Full Text] [Related]
8. More Severe Erosive Phenotype Despite Lower Circulating Autoantibody Levels in Dipeptidyl Peptidase-4 Inhibitor (DPP4i)-Associated Bullous Pemphigoid: A Retrospective Cohort Study.
Ständer S; Schmidt E; Zillikens D; Ludwig RJ; Kridin K
Am J Clin Dermatol; 2021 Jan; 22(1):117-127. PubMed ID: 33026629
[TBL] [Abstract][Full Text] [Related]
9. Clinical and immunological profiles of anti-BP230-type bullous pemphigoid: Restriction of epitopes to the C-terminal domain of BP230, shown by novel ELISAs of BP230-domain specific recombinant proteins.
Hayakawa T; Teye K; Hachiya T; Uehara R; Hashiguchi M; Kawakami T; Li X; Tsuchisaka A; Ohara K; Sogame R; Koga H; Hamada T; Ohata C; Furumura M; Ishii N; Fukano H; Shimozato K; Hashimoto T
Eur J Dermatol; 2016 Apr; 26(2):155-63. PubMed ID: 27087683
[TBL] [Abstract][Full Text] [Related]
10. Autoantibodies in lichen planus pemphigoides react with a novel epitope within the C-terminal NC16A domain of BP180.
Zillikens D; Caux F; Mascaro JM; Wesselmann U; Schmidt E; Prost C; Callen JP; Bröcker EB; Diaz LA; Giudice GJ
J Invest Dermatol; 1999 Jul; 113(1):117-21. PubMed ID: 10417629
[TBL] [Abstract][Full Text] [Related]
11. Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid.
Di Zenzo G; Thoma-Uszynski S; Fontao L; Calabresi V; Hofmann SC; Hellmark T; Sebbag N; Pedicelli C; Sera F; Lacour JP; Wieslander J; Bruckner-Tuderman L; Borradori L; Zambruno G; Hertl M
Clin Immunol; 2008 Sep; 128(3):415-26. PubMed ID: 18571472
[TBL] [Abstract][Full Text] [Related]
12. Immunoreactivity of bullous pemphigoid (BP) autoantibodies against the NC16A and C-terminal domains of the 180 kDa BP antigen (BP180): immunoblot analysis and enzyme-linked immunosorbent assay using BP180 recombinant proteins.
Nakatani C; Muramatsu T; Shirai T
Br J Dermatol; 1998 Sep; 139(3):365-70. PubMed ID: 9767278
[TBL] [Abstract][Full Text] [Related]
13. Cicatricial pemphigoid differs from bullous pemphigoid and pemphigoid gestationis regarding the fine specificity of autoantibodies to the BP180 NC16A domain.
Kromminga A; Sitaru C; Meyer J; Arndt R; Schmidt E; Christophers E; Bröcker EB; Zillikens D
J Dermatol Sci; 2002 Jan; 28(1):68-75. PubMed ID: 11916132
[TBL] [Abstract][Full Text] [Related]
14. IgE autoantibodies against the intracellular domain of BP180.
Dresow SK; Sitaru C; Recke A; Oostingh GJ; Zillikens D; Gibbs BF
Br J Dermatol; 2009 Feb; 160(2):429-32. PubMed ID: 18808416
[TBL] [Abstract][Full Text] [Related]
15. Cicatricial pemphigoid: IgA and IgG autoantibodies target epitopes on both intra- and extracellular domains of bullous pemphigoid antigen 180.
Schmidt E; Skrobek C; Kromminga A; Hashimoto T; Messer G; Bröcker EB; Yancey KB; Zillikens D
Br J Dermatol; 2001 Nov; 145(5):778-83. PubMed ID: 11736901
[TBL] [Abstract][Full Text] [Related]
16. BPDAI and ABSIS correlate with serum anti-BP180 NC16A IgG but not with anti-BP230 IgG in patients with bullous pemphigoid.
Daneshpazhooh M; Ghiasi M; Lajevardi V; Nasiri N; Balighi K; Teimourpour A; Khosravi H; Saeidi V; Mahmoudi H; Chams-Davatchi C
Arch Dermatol Res; 2018 Apr; 310(3):255-259. PubMed ID: 29423547
[TBL] [Abstract][Full Text] [Related]
17. A case of anti-BP230 antibody-positive bullous pemphigoid receiving DPP-4 inhibitor.
Sawada K; Sawada T; Kobayashi T; Fujiki A; Matsushita T; Kawara S; Izumi K; Nishie W; Shimizu H; Takehara K; Hamaguchi Y
Immunol Med; 2021 Mar; 44(1):53-55. PubMed ID: 32634333
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the combination of BP180-NC16a enzyme-linked immunosorbent assay and BP230 enzyme-linked immunosorbent assay in the diagnosis of bullous pemphigoid.
Yang B; Wang C; Chen S; Chen X; Lu X; Tian H; Yu M; Zhang D; Shi Z; Zhou G; Zhang F
Indian J Dermatol Venereol Leprol; 2012; 78(6):722-7. PubMed ID: 23075641
[TBL] [Abstract][Full Text] [Related]
19. Anti-BP230 IgE autoantibodies in bullous pemphigoid intraindividually correlate with disease activity.
Emtenani S; Linnemann BE; Recke A; von Georg A; Goletz S; Schmidt E; van Beek N
J Dermatol Sci; 2024 May; 114(2):64-70. PubMed ID: 38582700
[TBL] [Abstract][Full Text] [Related]
20. Autoantibody Profile Differentiates between Inflammatory and Noninflammatory Bullous Pemphigoid.
Izumi K; Nishie W; Mai Y; Wada M; Natsuga K; Ujiie H; Iwata H; Yamagami J; Shimizu H
J Invest Dermatol; 2016 Nov; 136(11):2201-2210. PubMed ID: 27424319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
